Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of total body irradiation (TBI) in combination with standard of care lymphodepletion with cyclophosphamide and fludarabine before tisagenlecleucel (Tisa-cel) and how well the combination works in patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). TBI is a common treatment that sends radiation (for example, through x-rays) to the entire body. Lymphodepleting chemotherapy, such as cyclophosphamide and fludarabine, along

Trial Details

NCT ID
NCT07676877
Phase
PHASE1
Sponsor
Nathan Denlinger
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Biospecimen Collection
  • Computed Tomography
  • Cyclophosphamide
  • Fludarabine
  • Leukapheresis
  • Positron Emission Tomography
Locations (sample)
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Eligible for standard of care anti-CD19 CAR-T treatment with Tisa-cel
  • Age ≥ 18 years
  • Biopsy-confirmed relapsed or refractory large B-cell lymphoma after 2 lines of prior therapy
  • Qualitative CD19 expression by either immunohistochemistry (IHC) or flow cytometry

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →